New treatments for COPD

Nature Reviews Drug Discovery

Volumn 1, Issue 6, 2002, Pages 437-446

  Barnes, Peter J ^a  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2 BROMOPHENYL) 3 (2 HYDROXY 4 NITROPHENYL)UREA; 1 [3 (4 BIPHENYLYLMETHYL) 4 HYDROXYCHROMAN 7 YL]CYCLOPENTANECARBOXYLIC ACID; 2 [2 PROPYL 3 [3 [2 ETHYL 4 (4 FLUOROPHENYL) 5 HYDROXYPHENOXY]PROPOXY]PHENOXY]BENZOIC ACID; 7 [3 [2 CYCLOPROPYLMETHYL 3 METHOXY 4 [(METHYLAMINO)CARBONYL]PHENOXY]PROPOXY] 3,4 DIHYDRO 8 PROPYL 2H 1 BENZOPYRAN 2 PROPANOIC ACID; AMFEBUTAMONE; AMOXICILLIN; ANTIBIOTIC AGENT; ANTIDEPRESSANT AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; ETANERCEPT; INFLIXIMAB; IPRATROPIUM BROMIDE; LEUKOTRIENE B4 RECEPTOR ANTAGONIST; MONOCLONAL ANTIBODY; NICOTINE; NITRIC OXIDE SYNTHASE INHIBITOR; NORTRIPTYLINE; OXITROPIUM BROMIDE; OXYGEN; PHOSPHODIESTERASE IV INHIBITOR; PLACEBO; SALBUTAMOL; TERBUTALINE; THEOPHYLLINE; TIOTROPIUM BROMIDE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNINDEXED DRUG; AUTACOID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; PROTEINASE INHIBITOR; TUMOR NECROSIS FACTOR ALPHA;

ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CIGARETTE SMOKING; CLINICAL TRIAL; DISEASE COURSE; DISEASE EXACERBATION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG SELECTIVITY; DRUG TARGETING; DRUG TOLERABILITY; GASTROINTESTINAL TOXICITY; HUMAN; INSOMNIA; MOLECULAR MECHANICS; NAUSEA; NICOTINE REPLACEMENT THERAPY; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; RESPIRATORY TRACT INFLAMMATION; REVIEW; SIDE EFFECT; TOBACCO DEPENDENCE; TREATMENT PLANNING; DRUG ANTAGONISM; SMOKING CESSATION;

BRONCHODILATOR AGENTS; HUMANS; INFLAMMATION MEDIATORS; INTERLEUKIN-10; NF-KAPPA B; PROTEASE INHIBITORS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SMOKING CESSATION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0036598241     PISSN: 14741776     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrd820     Document Type: Review

References (92)

1. Barnes, P. J. Chronic obstructive pulmonary disease. N. Engl. J. Med. 343, 269-280 (2000).
2. Barnes, P. J. Mechanisms in COPD: differences from asthma. Chest 117, 10S-14S (2000).
3. Saetta, M., Turato, G., Maestrelli, P., Mapp, C. E. & Fabbri, L. M. Cellular and structural bases of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 163, 1304-1309 (2001).
4. Barnes, P. J. New treatments for chronic obstructive pulmonary disease. Curr. Opin. Pharmacol. 1, 217-222 (2001).
5. Pauwels, R. A., Buist, S., Calverley, P. M., Jenkins, C. R. & Hurd, S. S. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am. J. Respir. Crit. Care Med. 163, 1256-1276 (2001).
6. Lopez, A. D. & Murray, C. C. The global burden of disease, 1990-2020. Nature Med. 4, 1241-1243 (1998).
7. 2-agonists for chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2, CD001104 (2000).
8. Van Noord, J. A. et al. Long-term treatment of chronic obstructive pulmonary disease with salmeterol and the additive effect of ipratropium. Eur. Respir. J. 15, 878-885 (2000).
9. Combivent Inhalation Study Group. Routine nebulized ipratropium and albuterol together are better than either alone in COPD. Chest 112, 1514-1521 (1997).
10. Barnes, P. J. Inhaled corticosteroids are not helpful in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 161, 342-344 (2000).
11. Calverley, P. M. Inhaled corticosteroids are beneficial in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 161, 341-342 (2000).
12. Papi, A. et al. Partial reversibility of airflow limitation and increased exhaled NO and sputum eosinophilia in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 162, 1773-1777 (2000).
13. Wedzicha, J. A. Domiciliary oxygen therapy services: clinical guidelines and advice for prescribers. Summary of a report of the Royal College of Physicians. J. R. Coll. Physicians, Lond. 33, 445-447 (1999).
14. Lacasse, Y. et al. Meta-analysis of respiratory rehabilitation in chronic obstructive pulmonary disease. Lancet 348, 1115-1119 (1996).
15. Davies, L., Angus, R. M. & Calverley P. M. Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled trial. Lancet 354, 456-460 (1999).
16. Barnes, P. J. Novel approaches and targets for treatment of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 160, S72-S79 (1999).
17. Shapiro, S. D. Animal models for COPD. Chest 117, 223S-227S (2000).
18. Hansel, T. T. & Barnes, P. J. New Drugs for Asthma and COPD (Karger, Basel, 2001).
19. Lancaster, T., Stead, L., Silagy, C. & Sowden, A. Effectiveness of interventions to help people stop smoking: findings from the Cochrane Library. Br. Med. J. 321, 355-358 (2000).
20. Jorenby, D. E. et al. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N. Engl. J. Med. 340, 685-691 (1999).
21. Tashkin, D. P. et al. Smoking cessation in patients with chronic obstructive pulmonary disease: a double-blind, placebo controlled, randomised trial. Lancet 357, 1571-1575 (2001).
22. Hughes, J. R., Stead, L. F. & Lancaster, T. Antidepressants for smoking cessation (Cochrane Review). Cochrane Database Syst. Rev. 4, CD000031 (2000).
23. Holm, K. J. & Spencer, C. M. Bupropion: a review of its use in the management of smoking cessation. Drugs 59, 1007-1024 (2000).
24. Disse, B., Speck, G. A., Rominger, K. L., Witek, T. J. & Hammer, R. Tiotropium (Spiriva): mechanistical considerations and clinical profile in obstructive lung disease. Life Sci. 64, 457-464 (1999).
25. Barnes, P. J. The pharmacological properties of tiotropium. Chest 117, 63S-66S (2000).
26. Littner, M. R. et al. Long-acting bronchodilation with once-daily dosing of tiotropium (Spiriva) in stable chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 161, 1136-1142 (2000).
27. Casaburi, R. et al. The spirometric efficacy of once-daily dosing with tiotropium in stable COPD: a 13-week multicenter trial. Chest 118, 1294-1302 (2000).
28. Van Noord, J. A., Bantje, T A., Eland, M. E., Korducki, L. & Cornelissen, P. J. A randomised controlled comparison of tiotropium and ipratropium in the treatment of chronic obstructive pulmonary disease. The Dutch Tiotropium Study Group. Thorax 55, 289-294 (2000).
29. Casaburi, R. et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur. Respir. J. 19, 217-224 (2002).
30. Vincken, W. et al. Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium. Eur. Respir. J. 19, 209-216 (2002).
31. Rutgers, S. R. et al. Ongoing airway inflammation in patients with COPD who do not currently smoke. Thorax 55, 12-18 (2000).
32. Hill, A. T., Bayley, D. & Stockley, R. A. The interrelationship of sputum inflammatory markers in patients with chronic bronchitis. Am. J. Respir. Crit. Care Med. 160, 893-898 (1999).
33. 4 receptor, BLT2. A new therapeutic target in inflammation and immunological disorders. J. Exp. Med. 192, 421-432 (2000).
34. 4 receptor antagonist LY29311: in vivo pulmonary studies. Naunyn Schmiedebergs Arch. Pharmacol. 361, 397-404 (2000).
35. 4. Eur. Respir. J. 15, 274-280 (2000).
36. Keatings, V. M., Collins, P. D., Scott, D. M. & Barnes, P. J. Differences in interleukin-8 and tumor necrosis factor-α in induced sputum from patients with chronic obstructive pulmonary disease or asthma. Am. J. Respir. Crit. Care Med. 153, 530-534 (1996).
37. Yang, X. D., Corvalan, J. R., Wang, P., Roy, C. M. & Davis, C. G. Fully human anti-interleukin-8 monoclonal antibodies: potential therapeutics for the treatment of inflammatory disease states. J. Leukocyte Biol. 66, 401-410 (1999).
38. Rossi, D. & Zlotnik, A. The biology of chemokines and their receptors. Annu. Rev. Immunol. 18, 217-242 (2000).
39. Traves, S. L., Culpitt, S., Russell, R. E. K., Barnes, P. J. & Donnelly, L. E. Elevated levels of the chemokines GRO-α and MCP-1 in sputum samples from COPD patients. Thorax (in the press).
40. White, J. R. et al. Identification of a potent, selective non-peptide CXCR2 antagonist that inhibits interleukin-8-induced neutrophil migration. J. Biol. Chem. 273, 10095-10098 (1998).
41. Hay, D. W. P. & Sarau, H. M. Interleukin-8 receptor antagonists in pulmonary diseases. Curr. Opin. Pharmacol. 1, 242-247 (2001).
42. De Boer, W. I. et al. Monocyte chemoattractant protein 1, interleukin 8, and chronic airways inflammation in COPD. J. Pathol. 190, 619-626 (2000).
43. De Godoy, I., Donahoe, M., Calhoun, W. J., Mancino, J. & Rogers, R. M. Elevated TNF-α production by peripheral blood monocytes of weight-losing COPD patients. Am. J. Respir. Crit. Care Med. 153, 633-637 (1996).
44. Markham, A. & Lamb, H. M. Infliximab: a review of its use in the management of rheumatoid arthritis. Drugs 59, 1341-1359 (2000).
45. Jarvis, B. & Faulds, D. Etanercept: a review of its use in rheumatoid arthritis. Drugs 57, 945-966 (1999).
46. Barlaam, B. et al. New α-substituted succinate-based hydroxamic acids as TNF-α convertase inhibitors. J. Med. Chem. 42, 4890-4908 (1999).
47. Rabinowitz, M. H. et al. Design of selective and soluble inhibitors of tumor necrosis factor-α converting enzyme (TACE). J. Med. Chem. 44, 4252-4267 (2001).
48. Montuschi, P. et al. Exhaled 8-isoprostane as an in vivo biomarker of lung oxidative stress in patients with COPD and healthy smokers. Am. J. Respir. Crit. Care Med. 162, 1175-1177 (2000).
49. Paredi, P. et al. Exhaled ethane, a marker of lipid peroxidation, is elevated in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 162, 369-373 (2000).
50. Macnee, W. Oxidants/antioxidants and COPD. Chest 117, 303S-317S (2000).
51. Grandjean, E. M., Berthet, P., Ruffmann, R. & Leuenberger, P. Efficacy of oral long-term N-acetylcysteine in chronic bronchopulmonary disease: a meta-analysis of published double-blind, placebo-controlled clinical trials. Clin. Ther. 22, 209-221 (2000).
52. Poole, P. J. & Black, P. N. Oral mucolytic drugs for exacerbations of chronic obstructive pulmonary disease: systematic review. Br. Med. J. 322, 1271-1274 (2001).
53. Cuzzocrea, S., Riley, D. P., Caputi, A. P. & Salvemini, D. Antioxidant therapy: a new pharmacological approach in shock, inflammation, and ischemia/reperfusion injury. Pharmacol. Rev. 53, 135-159 (2001).
54. Ichinose, M., Sugiura, H., Yamagata, S., Koarai, A. & Shirato, K. Increase in reactive nitrogen species production in chronic obstructive pulmonary disease airways. Am. J. Respir. Crit. Care Med. 160, 701-706 (2000).
55. Hobbs, A. J., Higgs, A. & Moncada, S. Inhibition of nitric oxide synthase as a potential therapeutic target. Annu. Rev. Pharmacol. Toxicol. 39, 191-220 (1999).
56. Vestbo, J. et al. Long-term effect of inhaled budesionide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 353, 1819-1823 (1999).
57. Pauwels, R. A. et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. N. Engl. J. Med. 340, 1948-1953 (1999).
58. Burge, P. S. et al. Randomised, double-blind, placebo-controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease; the ISOLDE trial. Br. Med. J. 320, 1297-1303 (2000).
59. Lung Health Study Research Group. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N. Engl. J. Med. 343, 1902-1909 (2000).
60. Keatings, V. M., Jatakanon, A., Worsdell, Y. M. & Barnes, P. J. Effects of inhaled and oral glucocorticoids on inflammatory indices in asthma and COPD. Am. J. Respir. Crit. Care Med. 155, 542-548 (1997).
61. Culpitt, S. V., Nightingale, J. A. & Barnes, P. J. Effect of high dose inhaled steroid on cells, cytokines and proteases in induced sputum in chronic obstructive pulmorary disease. Am. J. Respir. Crit. Care Med. 160, 1635-1639 (1999).
62. Nightingale, J. A., Rogers, D. F., Chung, K. F. & Barnes, P. J. No effect of inhaled budesonide on the response to inhaled ozone in normal subjects. Am. J. Respir. Crit. Care Med. 161, 479-486 (2000).
63. Meagher, L. C., Cousin, J. M., Seckl, J. R. & Haslett, C. Opposing effects of glucocorticoids on the rate of apoptosis in neutrophilic and eosinophilic granulocytes. J. Immunol. 156, 4422-4428 (1996).
64. Ito, K. et al. Cigarette smoking reduces histone deacetylase 2 expression, enhances cytokine expression and inhibits glucocorticoid actions in alveolar macrophages. FASEB J. 15, 1100-1102 (2001).
65. Souness, J. E., Aldous, D. & Sargent, C. Immunosuppressive and anti-inflammatory effects of cyclic AMP phosphodiesterase (PDE) type 4 inhibitors. Immunopharmacology 47, 127-162 (2000).
66. Spond, J. et al. Comparison of PDE4 inhibitors, rolipram and SB 207499 (Ariflo), in a rat model of pulmonary neutrophilia. Pulm. Pharmacol. Ther. 14, 157-164 (2001).
67. Bundschuh, D. S. et al. In vivo efficacy in airway disease models of roflumilast, a novel orally active PDE4 inhibitor. J. Pharmacol. Exp. Ther. 297, 280-290 (2001).
68. Compton, C. H. et al. Cilomilast, a selective phosphodiesterase-4 inhibitor for treatment of patients with chronic obstructive pulmonary disease: a randomised, dose-ranging study. Lancet 358, 265-270 (2001).
69. Delhase, M., Li, N. & Karin, M. Kinase regulation in inflammatory response. Nature 406, 367-368 (2000).
70. Nasuhara, Y., Adcock, I. M., Catley, M., Barnes, P. J. & Newton, R. Differential IKK activation and IκBα degradation by interleukin-1β and tumor necrosis factor-α in human U937 monocytic, cells: evidence for additional regulatory steps in κB-dependent transcription. J. Biol. Chem. 274, 19965-19972 (1999).
71. Davenpeck, K. L., Berens, K. L., Dixon, R. A., Dupre, B. & Bochner, B. S. Inhibition of adhesion of human neutrophils and eosinophils to P-selectin by the sialyl Lewis antagonist TBC1269: preferential activity against neutrophil adhesion in vitro. J. Allergy Clin. Immunol. 105, 769-775 (2000).
72. Noguera, A. et al. Enhanced neutrophil response in chronic obstructive pulmonary disease. Thorax 56, 432-437 (2001).
73. Takanashi, S. et al. Interleukin-10 level in sputum is reduced in bronchial asthma, COPD and in smokers. Eur. Respir. J. 14, 309-314 (1999).
74. Fedorak, R. N. et al. Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease. Gastroenterology 119, 1473-1482 (2000).
75. Carter, A. B., Monick, M. M. & Hunninghake, G. W. Both erk and p38 kinases are necessary for cytokine gene transcription. Am. J. Respir. Cell Mol. Biol. 20, 751-758 (1999).
76. Meja, K. K. et al. p38 MAP kinase and MKK-1 cooperate in the generation of GM-CSF from LPS-stimulated human monocytes by an NF-κB-independent mechanism. Br. J. Pharmacol. 131, 1143-1153 (2000).
77. Lee, J. C. et al. Inhibition of p38 MAP kinase as a therapeutic strategy. Immunopharmacology 47, 185-201 (2000).
78. Underwood, D. C. et al. SB 239063, a p38 MAPK inhibitor, reduces neutrophilia, inflammatory cytokines, MMP-9, and fibrosis in lung. Am. J. Physiol. Lung Cell Mol. Physiol. 279, L895-L902 (2000).
79. Sasaki, T. et al. Function of PI3Kγ in thymocyte development, T cell activation, and neutrophil migration. Science 287, 1040-1046 (2000).
80. Stockley, R. A. Neutrophils and protease/antiprotease imbalance. Am. J. Respir. Crit. Care Med. 160, S49-S52 (1999).
81. Shapiro, S. D. & Senior, R. M. Matrix metalloproteinases. Matrix degradation and more. Am. J. Respir. Cell Mol. Biol. 20, 1100-1102 (1999).
82. Kawabata, K. et al. ONO-5046, a novel inhibitor of human neutrophil elastase. Biochem. Biophys. Res. Commun. 177, 814-820 (1991).
83. Fujie, K. et al. Inhibition of elastase-induced acute inflammation and pulmonary emphysema in hamsters by a novel neutrophil elastase inhibitor FR901277. Inflamm. Res. 48, 160-167 (1999).
84. Punturieri, A. et al. Regulation of elastinolytic cysteine proteinase activity in normal and cathepsin K-deficient human macrophages. J. Exp. Med. 192, 789-800 (2000).
85. Leung-Toung, R., Li, W., Tam, T. F. & Karimian, K. Thiol-dependent enzymes and their inhibitors: a review. Curr. Med. Chem. 9, 979-1002 (2002).
86. Russell, R. E. et al. Release and activity of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 by alveolar macrophages from patients with chronic obstructive pulmonary disease. Am. J. Respir. Cell Mol. Biol. 26, 602-609 (2002).
87. Massaro, G. & Massaro, D. Retinoic acid treatment abrogates elastase-induced pulmonary emphysema in rats. Nature Med. 3, 675-677 (1997).
88. Belloni, P. N., Garvin, L., Mao, C. P., Beiley-Healy, I. & Leaffer, D. Effects of all-trans-retinoic acid in promoting alveolar repair. Chest 117, 235S-241S (2000).
89. Mao, J. T. et al. A pilot study of all-trans-retinoic acid for the treatment of human emphysema. Am. J. Respir. Crit. Care Med. 165, 718-723 (2002).
90. Barnes, P. J. Molecular genetics of chronic obstructive pulmonary disease. Thorax 54, 245-252 (1999).
91. Kharitonov, S. A. & Barnes, P. J. Exhaled markers of pulmonary disease. Am. J. Respir. Crit. Care Med. 163, 1693-1772 (2001).
92. Fletcher, C. & Peto, R. The natural history of chronic airflow obstruction. Br. Med. J. 1, 1645-1648 (1977).